Serotonin Receptor Screening for Anti-Emetic Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-emetic compounds for treating emesis often have undesirable side effects such as sedation or anxiety, and there is a need for improved treatments with better side effect profiles.
Innovation Solution
A novel screening method that identifies compounds with anti-emetic properties by assessing their binding affinity and efficacy on serotonin receptors, particularly focusing on 5-HT1a, 5-HT1d, and 5-HT7 receptors, where compounds acting as agonists to 5-HT1a and 5-HT1d receptors with minimal or no activity on the 5-HT7 receptor are preferred to minimize anxiety side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-emetic compounds are used to treat emesis, then emesis is reduced, but undesirable side effects such as sedation or anxiety occur
Solution Approach 1:
The patent segments the serotonin receptor system into multiple subtypes (5-HT1a, 5-HT1d, 5-HT7) and targets them differently. By using a multi-receptor profile approach where 5-HT1a and 5-HT1d are activated but 5-HT7 is blocked, the patent achieves anti-emetic effectiveness while avoiding the anxiety side effects associated with 5-HT1a agonists alone.
Solution Approach 2:
The patent applies local quality by differentiating the action at different receptor locations. The compound acts as an agonist at 5-HT1a and 5-HT1d receptors (promoting anti-emetic effect) while acting as an antagonist at 5-HT7 receptors (preventing anxiety). This selective localized action at different receptor subtypes resolves the contradiction between effectiveness and side effects.
2Device complexity
If compounds are screened based on traditional single-receptor assays, then screening is simple, but the ability to identify compounds with improved side effect profiles is limited
Solution Approach 1:
The patent creates a multi-functional screening assay that simultaneously evaluates binding affinity and functional efficacy at multiple serotonin receptor subtypes (5-HT1a, 5-HT1d, and 5-HT7). This universal assay platform can identify compounds with desirable anti-emetic properties while filtering out those with problematic side effect profiles, thereby improving reliability without excessive complexity.
Solution Approach 2:
The screening method incorporates feedback mechanisms where compounds are evaluated on multiple parameters (binding affinity at 5-HT1a, 5-HT1d, and 5-HT7; functional efficacy). The results feed back into the selection process, allowing iterative optimization of the compound library to favor candidates with the desired receptor profile that balances anti-emetic effectiveness with minimal side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively identifies compounds that provide anti-emetic benefits with reduced anxiety, as demonstrated by the use of 8-OH-DPAT enantiomers, which show significant protection against emesis with minimal anxiogenic effects, allowing for the development of pharmaceutical compositions with improved therapeutic profiles.
Implementation Method 1
contacting a non-endogenous candidate compound with a serotonin receptor selected from the group consisting of: (i) an endogenous version of a 5-HT1a receptor; (ii) a non-endogenous version of a 5-HT1a receptor; (iii) an endogenous version of a 5-HT1d receptors; and (iv) a non-endogenous version of a 5-HT1d receptor
Data Source
AI summary
A screening method for identifying compounds with anti-emetic properties by evaluating binding affinity and efficacy of the compounds with respect to the 5-HT1a, 5-HT1d, and 5-HT7 receptors.